Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company focused on therapies for people impacted by kidney disease, and its news flow reflects this specialization. Company announcements frequently highlight progress with Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. Updates include prescribing access among dialysis organizations, clinical trial data such as post-hoc analyses from the INNO2VATE trials, and real-world studies like VOICE and VOCAL that examine mortality, hospitalization, and dosing strategies.
News releases also cover Akebia’s rare kidney disease pipeline, including praliciguat and AKB-097. Investors can follow milestones such as the first patient dosed in a Phase 2 trial of praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS), plans to evaluate praliciguat in other rare podocytopathies, and the planned Phase 2 basket study of AKB-097 across complement-mediated rare kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional pipeline updates may involve AKB-9090, a HIF-PH inhibitor entering Phase 1 for acute kidney injury associated with cardiac surgery.
Akebia’s news stream also includes financial results, stock option inducement grants under Nasdaq Listing Rule 5635(c)(4), licensing and supply agreements such as amendments to its Vafseo license with Medice in Europe and certain other countries, and participation in healthcare and investor conferences. For investors tracking AKBA, this news page provides a centralized view of clinical, regulatory, commercial, and corporate developments that shape the company’s kidney disease franchise and pipeline trajectory.
Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to eight new employees on December 31, 2020, totaling 89,000 shares with an exercise price of $2.80 per share. This decision aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment. The options vest over four years, with 25% vested after one year and the remainder quarterly. The options are valid for ten years and are governed by the company's Inducement Award Program.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, will participate in the 39th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2021, at 2:50 p.m. EST, led by John P. Butler, President and CEO. Interested parties can access the live webcast and replay on the Investors section of Akebia's website. Founded in 2007 and based in Cambridge, Massachusetts, Akebia is focused on developing therapeutics for kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) announced a virtual panel scheduled for December 16, 2020, aimed at discussing hyperphosphatemia management in patients with chronic kidney disease (CKD) on dialysis. The panel will feature insights from kidney care professionals and emphasize the importance of a multidisciplinary care approach and telehealth monitoring. Akebia's AURYXIA® (ferric citrate) is FDA-approved for controlling serum phosphorus levels in CKD patients on dialysis and treating iron deficiency anemia in CKD patients not on dialysis.
Akebia Therapeutics (Nasdaq: AKBA) announced the granting of stock options to 7 newly-hired employees on November 30, 2020. The options, totaling 49,000 shares, have an exercise price of $3.31 per share, equivalent to the stock's closing price on the grant date. These options will vest over four years, with 25% vesting after one year and the remainder quarterly, contingent on continued employment. This move adheres to Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new hires.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 3, 2020. The company’s President, John P. Butler, and CFO, David A. Spellman, will engage in virtual meetings. A recording of their presentation will be accessible on the conference site and Akebia's investor page from November 24 to December 3, 2020. Akebia, founded in 2007 and based in Cambridge, Massachusetts, aims to enhance the quality of life for those affected by kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) has been ranked 10th on Deloitte's Technology Fast 500, reflecting a staggering revenue growth of 21,724% from 2016 to 2019. This rapid growth is attributed to the strategic merger with Keryx Biopharmaceuticals on December 12, 2018, which enabled revenue from the commercial product AURYXIA®. Additionally, Akebia's collaboration revenue from the development of vadadustat, an investigational treatment for anemia due to chronic kidney disease, further supports this growth. The company is recognized for its commitment to improving the lives of kidney disease patients.
Akebia Therapeutics (AKBA) announced the publication of a manuscript in Nephrology Dialysis Transplantation, detailing the study design and methodology of its Phase 3 INNO2VATE program. This research evaluates vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treating anemia due to chronic kidney disease. The manuscript highlights that demographics of study participants align with typical dialysis-dependent CKD patients, suggesting broad applicability of results. Vadadustat met both primary and key secondary efficacy and safety endpoints compared to darbepoetin alfa.
Akebia Therapeutics (Nasdaq: AKBA) announced its Q3 2020 financial results, reporting total revenue of $60 million, down from $92 million in Q3 2019, primarily due to decreased collaboration revenue. Despite a 14.6% increase in net product revenue for Auryxia® to $34.4 million, net loss widened to $60 million from $54.6 million. Akebia completed a pre-NDA meeting with the FDA for vadadustat, an oral treatment for anemia due to chronic kidney disease, targeting a $2 billion market. The company aims to submit an NDA in early 2021.
On November 3, 2020, Akebia Therapeutics (Nasdaq: AKBA) announced it granted stock options to 6 newly-hired employees, totaling 27,000 shares. The options, priced at $2.22 per share, reflect the company's closing stock price on the grant date of October 30, 2020. Each option vests over four years, with 25% vesting on the first anniversary and the remainder quarterly, conditional on continued employment. These grants align with Nasdaq Listing Rule 5635(c)(4), enhancing the company’s talent acquisition strategy.
Akebia Therapeutics (Nasdaq: AKBA) announced it will release its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before market opening. A conference call to discuss these results and business updates will take place at 9:00 a.m. ET on the same day, accessible via phone and webcast. The call will be archived online for later access. Akebia is committed to improving the lives of those with kidney disease and has been operational since 2007, headquartered in Cambridge, Massachusetts.
FAQ
What is the current stock price of Akebia Therapeut (AKBA)?
What is the market cap of Akebia Therapeut (AKBA)?
